Indicated for:

Plaque Psoriasis:

• The treatment of moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy. 

Psoriatic Arthritis:

• The treatment of active psoriatic arthritis (PsA) in patients 2 years of age and older. 

Ankylosing Spondylitis:

• The treatment of adult patients with active ankylosing spondylitis (AS).

Non-Radiographic Axial Spondyloarthritis:

• The treatment of adult patients with active non-radiographic axial spondyloarthritis (nraxSpA) with objective signs of inflammation.

Enthesitis-Related Arthritis:

• The treatment of active enthesitis-related arthritis (ERA) in patients 4 years of age and older.

COSENTYX may be administered with or without methotrexate.

COSENTYX may increase the risk of infections. Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with COSENTYX. Do not administer COSENTYX to patients with active TB infection.

Exercise caution when considering the use of COSENTYX in patients with a chronic infection or a history of recurrent infection.

Caution should be used when prescribing COSENTYX to patients with inflammatory bowel disease. Exacerbations, in some cases serious, occurred in COSENTYX treated patients during clinical trials in plaque psoriasis, psoriatic arthritis and ankylosing spondylitis. In addition, new onset inflammatory bowel disease cases occurred in clinical trials with COSENTYX.

Prior to initiating therapy with COSENTYX, consider completion of all age appropriate immunizations according to current immunization guidelines.

Patients treated with COSENTYX should not receive live vaccines. Non-live vaccinations received during a course of COSENTYX may not elicit an immune response sufficient to prevent disease.

Adult patients may self-administer COSENTYX or be injected by a caregiver after proper training in subcutaneous injection technique using the Sensoready pen.

Pediatric patients should not self-administer COSENTYX using the Sensoready pen. An adult caregiver should prepare and inject COSENTYX after proper training in subcutaneous injection technique using the Sensoready pen.

Neutropenia was observed in clinical trials.

The formation of CYP450 enzymes can be altered by increased levels of certain cytokines (e.g., IL-1, IL-6, IL-10, TNFα, IFN) during chronic inflammation.

Upon initiation or discontinuation of COSENTYX in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect or drug concentration and consider dosage adjustment of the CYP450 substrate as needed.

There are no adequate and well controlled trials of COSENTYX in pregnant women.

It is not known whether secukinumab is excreted in human milk or absorbed systemically after ingestion.

GoToSource

• Use in patients under 2 years of age. GoToSource

• Ichthyoses. GoToSource

• Hidradenitis suppurativa. GoToSource

• Pyoderma gangrenosum. GoToSource

• Noninfectious uveitis. GoToSource

Neutropenia (low level of neutrophils a type of white blood cell), anti-secukinumab antibodies and hypersensitivity reactions. GoToSource

Hypertension (high blood pressures) and inflammatory bowel disease. GoToSource

Anaphylaxis (potentially life-threatening allergic reaction), pruritus (severe itching), melanoma, bladder cancer and thyroid cancer. GoToSource

Serious allergic reactions and infections, upper respiratory infections, oral herpes, pharyngitis (inflammation of the pharynx), urticaria (hives), rhinorrhea (excessive nasal discharge) and exacerbation of crohn’s disease. GoToSource

Lawsuits filed for serious infections, inflammatory bowel disease, liver injury and neutropenia.